AR049405A1 - Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo - Google Patents
Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismoInfo
- Publication number
- AR049405A1 AR049405A1 ARP050102539A ARP050102539A AR049405A1 AR 049405 A1 AR049405 A1 AR 049405A1 AR P050102539 A ARP050102539 A AR P050102539A AR P050102539 A ARP050102539 A AR P050102539A AR 049405 A1 AR049405 A1 AR 049405A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pyridyl
- dimethyl
- manufacture
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 diketopiperazine compound Chemical class 0.000 abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 abstract 1
- 101800000989 Oxytocin Proteins 0.000 abstract 1
- 102000004279 Oxytocin receptors Human genes 0.000 abstract 1
- 108090000876 Oxytocin receptors Proteins 0.000 abstract 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 abstract 1
- 206010036595 Premature delivery Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 abstract 1
- 229960001723 oxytocin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Un compuesto de dicetopiperazina que tiene la formula (1): en la que R1 es 2-indanilo, R2 es 1-metilpropilo, R3 es un grupo seleccionado entre 2,6-dimetil-3-piridilo o 4,6-dimetil-3-piridilo; R4 representa metilo y R5 representa H o metilo, o, R4 y R5 junto con el átomo de N al que están unidos representan morfolino, y sus derivados farmacéuticamente aceptables. Composicion farmacéutica que comprende al compuesto descrito, junto con uno o más vehículos farmacéuticamente aceptables. Uso del compuesto para la fabricacion de un medicamento para antagonizar los efectos de la oxitocina en el receptor de oxitocina, util para el tratamiento de una o más enfermedades o afecciones seleccionadas entre parto prematuro, dismenorrea, endometriosis e hiperplasia prostática benigna. Procedimientos para la preparacion de dicho compuesto. Reivindicacion 1: Un compuesto de dicetopiperazina caracterizada porque tiene la formula (1): en la que R1 es 2-indanilo, R2 es 1-metilpropilo, R3 es un grupo seleccionado entre 2,6-dimetil-3-piridilo o 4,6-dimetil-3-piridilo; R4 representa metilo y R5 representa H o metilo, o, R4 y R5 junto con el átomo de N al que están unidos representan morfolino, y sus derivados farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0414093.5A GB0414093D0 (en) | 2004-06-23 | 2004-06-23 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049405A1 true AR049405A1 (es) | 2006-07-26 |
Family
ID=32800053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102539A AR049405A1 (es) | 2004-06-23 | 2005-06-21 | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo |
Country Status (30)
| Country | Link |
|---|---|
| US (9) | US7550462B2 (es) |
| EP (2) | EP1758886B1 (es) |
| JP (2) | JP5405019B2 (es) |
| KR (1) | KR101186447B1 (es) |
| CN (1) | CN1972924B (es) |
| AR (1) | AR049405A1 (es) |
| AU (1) | AU2005256470B2 (es) |
| BR (1) | BRPI0512376A (es) |
| CA (1) | CA2571527C (es) |
| CY (1) | CY1116183T1 (es) |
| DK (1) | DK1758886T3 (es) |
| ES (1) | ES2537801T3 (es) |
| GB (1) | GB0414093D0 (es) |
| HK (1) | HK1208669A1 (es) |
| HR (1) | HRP20150401T1 (es) |
| HU (1) | HUE025869T2 (es) |
| IL (2) | IL179905A0 (es) |
| MA (1) | MA28675B1 (es) |
| MX (1) | MXPA06014545A (es) |
| MY (1) | MY143578A (es) |
| NO (1) | NO338769B1 (es) |
| NZ (1) | NZ551733A (es) |
| PE (1) | PE20060477A1 (es) |
| PL (1) | PL1758886T3 (es) |
| PT (1) | PT1758886E (es) |
| RU (1) | RU2382038C2 (es) |
| SI (1) | SI1758886T1 (es) |
| TW (1) | TWI348466B (es) |
| WO (1) | WO2006000399A1 (es) |
| ZA (1) | ZA200610022B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| WO2003106656A2 (en) | 2002-06-17 | 2003-12-24 | Thrasos, Inc. | Single domain tdf-related compounds and analogs thereof |
| GB0314738D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| EP2789342A1 (en) | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| EP2927241A1 (en) | 2005-09-20 | 2015-10-07 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| WO2011051814A1 (en) | 2009-10-30 | 2011-05-05 | Glaxo Group Limited | Novel crystalline forms of (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - dimethyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoethyl] -6- [(1s) - 1 -methylpropyl] -2,5- piperazinedione |
| SG11201804789QA (en) | 2016-01-04 | 2018-07-30 | ObsEva SA | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| WO2017203012A1 (en) * | 2016-05-27 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Epelsiban for use in the treatment of adenomyosis |
| SG11201900461UA (en) | 2016-07-21 | 2019-02-27 | ObsEva SA | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| EP3805763A4 (en) * | 2018-05-29 | 2022-03-09 | Kao Corporation | SHEET COMFORT EVOCATION PERFORMANCE EVALUATION METHOD AND COMFORT EVOCATION SHEET |
| US11361161B2 (en) | 2018-10-22 | 2022-06-14 | Verint Americas Inc. | Automated system and method to prioritize language model and ontology expansion and pruning |
| WO2021043726A1 (en) | 2019-09-03 | 2021-03-11 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596819A (en) | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| DE3830096A1 (de) | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5817751A (en) | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
| GB2326639A (en) | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
| KR20010034469A (ko) | 1998-01-29 | 2001-04-25 | 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 | Ｎ-[(지방족 또는 방향족)카보닐]-2-아미노아세트아미드화합물 및 환화 화합물의 제조방법 |
| US6107274A (en) | 1998-03-16 | 2000-08-22 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0314733D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| GB0414092D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-06-23 GB GBGB0414093.5A patent/GB0414093D0/en not_active Ceased
-
2005
- 2005-06-21 RU RU2007102274/04A patent/RU2382038C2/ru not_active IP Right Cessation
- 2005-06-21 PT PT57555633T patent/PT1758886E/pt unknown
- 2005-06-21 HU HUE05755563A patent/HUE025869T2/en unknown
- 2005-06-21 KR KR1020067027107A patent/KR101186447B1/ko not_active Expired - Fee Related
- 2005-06-21 PL PL05755563T patent/PL1758886T3/pl unknown
- 2005-06-21 TW TW094120517A patent/TWI348466B/zh not_active IP Right Cessation
- 2005-06-21 DK DK05755563T patent/DK1758886T3/da active
- 2005-06-21 ES ES05755563.3T patent/ES2537801T3/es not_active Expired - Lifetime
- 2005-06-21 SI SI200531963T patent/SI1758886T1/sl unknown
- 2005-06-21 HR HRP20150401TT patent/HRP20150401T1/hr unknown
- 2005-06-21 CN CN2005800210140A patent/CN1972924B/zh not_active Expired - Fee Related
- 2005-06-21 BR BRPI0512376-3A patent/BRPI0512376A/pt not_active Application Discontinuation
- 2005-06-21 EP EP05755563.3A patent/EP1758886B1/en not_active Expired - Lifetime
- 2005-06-21 WO PCT/EP2005/006760 patent/WO2006000399A1/en not_active Ceased
- 2005-06-21 US US11/630,179 patent/US7550462B2/en not_active Expired - Fee Related
- 2005-06-21 MY MYPI20052837A patent/MY143578A/en unknown
- 2005-06-21 AR ARP050102539A patent/AR049405A1/es not_active Application Discontinuation
- 2005-06-21 CA CA2571527A patent/CA2571527C/en not_active Expired - Fee Related
- 2005-06-21 JP JP2007517197A patent/JP5405019B2/ja not_active Expired - Fee Related
- 2005-06-21 NZ NZ551733A patent/NZ551733A/en not_active IP Right Cessation
- 2005-06-21 MX MXPA06014545A patent/MXPA06014545A/es active IP Right Grant
- 2005-06-21 EP EP15157368.0A patent/EP2918580A1/en not_active Withdrawn
- 2005-06-21 AU AU2005256470A patent/AU2005256470B2/en not_active Ceased
- 2005-06-22 PE PE2005000714A patent/PE20060477A1/es active IP Right Grant
-
2006
- 2006-11-30 ZA ZA200610022A patent/ZA200610022B/en unknown
- 2006-12-07 IL IL179905A patent/IL179905A0/en not_active IP Right Cessation
- 2006-12-21 MA MA29549A patent/MA28675B1/fr unknown
-
2007
- 2007-01-10 NO NO20070173A patent/NO338769B1/no not_active IP Right Cessation
- 2007-07-23 HK HK15109142.1A patent/HK1208669A1/en unknown
-
2009
- 2009-06-08 US US12/480,182 patent/US20090247541A1/en not_active Abandoned
-
2010
- 2010-08-04 US US12/850,386 patent/US7919492B2/en not_active Expired - Fee Related
-
2011
- 2011-02-25 US US13/035,366 patent/US8202864B2/en not_active Expired - Fee Related
-
2012
- 2012-04-19 US US13/451,196 patent/US20120202811A1/en not_active Abandoned
- 2012-10-05 JP JP2012223526A patent/JP5503709B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-20 US US13/897,853 patent/US8742099B2/en not_active Expired - Fee Related
-
2014
- 2014-04-25 US US14/261,994 patent/US20140235639A1/en not_active Abandoned
-
2015
- 2015-02-16 US US14/623,098 patent/US20150157640A1/en not_active Abandoned
- 2015-03-02 IL IL237513A patent/IL237513A0/en unknown
- 2015-04-08 CY CY20151100339T patent/CY1116183T1/el unknown
- 2015-10-13 US US14/881,322 patent/US9408851B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049405A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR038818A1 (es) | Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| UY28578A1 (es) | Derivados de amida | |
| AR054612A1 (es) | Derivados de espiroquetas y composiciones farmaceuticas para su utilizacion como agente terapeutico para diabetes | |
| NO20085077L (no) | Nye forbindelser | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| TW200612936A (en) | Indole derivatives | |
| AR035651A1 (es) | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| IL180495A (en) | Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| SE0402925D0 (sv) | Novel Compounds | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| DK1583538T3 (da) | Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme | |
| AR049651A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, uso del compuesto para la fabricacion de un medicamento y procedimiento para la preparacion del mismo | |
| AR040441A1 (es) | Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento | |
| AR035110A1 (es) | Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
| DE60134735D1 (de) | Neue neurokinin-antagonisten zum gebrauch als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |